{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:35:01Z","timestamp":1790440501947,"version":"4.1.0"},"reference-count":35,"publisher":"Tech Science Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2024.049054","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:04:13Z","timestamp":1731398653000},"page":"57-65","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab"],"prefix":"10.32604","volume":"33","author":[{"given":"JUNG YONG","family":"HONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOON OH","family":"PARK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RYUL","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SUNG HEE","family":"LIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SEUNG TAE","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOO KYUNG","family":"PARK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MINSUK","family":"KWON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MINAE","family":"AN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/ijms17050791","article-title":"Circulating MicroRNAs as biomarkers in biliary tract cancers","volume":"17","author":"Letelier","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.ctarc.2021.100354","article-title":"Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treatment and Research Communications"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/cncr.32463","article-title":"Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes","volume":"125","author":"Lowery","year":"2019","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nature Reviews Immunology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"International Journal of Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1073274820948047","DOI":"10.1177\/1073274820948047","article-title":"Immunotherapy in biliary tract cancer: Worthy of a second look","volume":"27","author":"Ricci","year":"2020","journal-title":"Cancer Control: Journal of the Moffitt Cancer Center"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","article-title":"Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Cancer Discovery"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Annals of Oncology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Research"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref19","first-page":"e126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"Journal of Clinical Investigation Insight"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"Journal of Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"845\u2013865.E7","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","article-title":"A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"The Oncologist"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cells12162098","article-title":"Lacking immunotherapy biomarkers for biliary tract cancer: A comprehensive systematic literature review and meta-analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e003214","DOI":"10.1136\/jitc-2021-003214","article-title":"Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes","volume":"9","author":"Chen","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e2200003","DOI":"10.1200\/PO.22.00003","article-title":"Tumor mutational burden is a potential predictive biomarker for response to immune checkpoint inhibitors in patients with advanced biliary tract cancer","volume":"6","author":"Liddell","year":"2022","journal-title":"JCO Percision Oncology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2022.09.014","article-title":"Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer","volume":"176","author":"Kim","year":"2022","journal-title":"European Journal of Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.3390\/cancers15215285","volume":"15","author":"Pettinella","year":"2023","journal-title":"Cancers"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1158\/1078-0432.CCR-22-1386","volume":"28","author":"Rochigneux","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"335-346.E3","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-020-02558-z","volume":"69","author":"Trefny","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.3390\/cancers12113285","article-title":"The immune checkpoint PD-1 in natural killer cells: Expression, function and targeting in tumour immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e001933","DOI":"10.1136\/jitc-2020-001933","article-title":"Expanded human NK cells from lung cancer patients sensitize patients\u2019 PDL1-negative tumors to PD1-blockade therapy","volume":"9","author":"Poznanski","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/1759-7714.13677","article-title":"Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer","volume":"11","author":"Choi","year":"2020","journal-title":"Thoracic Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e000753","DOI":"10.1136\/esmoopen-2020-000753","article-title":"Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer","volume":"5","author":"Fasano","year":"2020","journal-title":"ESMO Open"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.3390\/cancers14174229","article-title":"Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1\/2a trial","volume":"14","author":"Leem","year":"2022","journal-title":"Cancers"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/or\/v33n1\/59090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:19:45Z","timestamp":1741328385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n1\/59090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.049054","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}